; (D) any barriers experienced by researchers or health care professionals in accessing the biospecimens and corresponding clinical demographic data necessary for use in research; and (E) any recommendations with respect to improving the biospecimen and biorepository research efforts under this subsection. (10) Definitions For purposes of this subsection: (A) Award The term award includes a grant, contract, cooperative agreement, or other transaction determined by the Secretary. (B) Biospecimen The term biospecimen includes— (i) solid tumor tissue or bone marrow; (ii) normal or control tissue; (iii) blood and plasma; (iv) DNA and RNA extractions; (v) familial DNA; and (vi) any other sample required by the Secretary. (C) Clinical and demographic information The term clinical and demographic information includes— (i) date of diagnosis; (ii) age at diagnosis; (iii) the patient’s gender, race, ethnicity, and environmental exposures; (iv) extent of disease at enrollment; (v) site of metastases; (vi) location of primary tumor coded; (vii) histologic diagnosis; (viii) tumor marker data when available; (ix) treatment and outcome data; (x) information related to specimen quality; and (xi) any other information required by the Secretary. ; and (2) in subsection (d)— (A) by striking and section 399E–1 and inserting and sections 317U, 399E–1, 417H, and 417H–1 ; (B) by striking 2009 through 2013 and inserting 2018 through 2022 ; and (C) by striking such purpose and inserting such purposes . 102. Improving Childhood Cancer Surveillance Section 399E–1 of the Public Health Service Act ( 42 U.S.C. 280e–3a ) is amended— (1) by redesignating subsection (b) as subsection (d)